Naproxen and Coveram Interaction Guidelines

Mechanism of Interaction and Risk Assessment

• The American College of Cardiology and other guideline societies recommend caution when using NSAIDs like naproxen with ACE inhibitors like perindopril, as they may reduce the antihypertensive effectiveness and increase the risk of renal impairment 1, 2
• The European Society of Cardiology notes that NSAIDs can attenuate the blood pressure-lowering effects of antihypertensive medications, including ACE inhibitors, by inhibiting prostaglandin synthesis 1, 2
• The combination of naproxen and Coveram may result in reduced effectiveness of antihypertensive therapy, potentially elevated blood pressure, and increased risk of acute renal impairment, particularly in patients with pre-existing renal dysfunction 1, 2
• The American Heart Association recommends monitoring for electrolyte disturbances, such as hyperkalemia, when using this combination, especially in susceptible patients 3

Recommendations for Clinical Management

• The American College of Cardiology recommends closely monitoring blood pressure when initiating naproxen in patients on Coveram to ensure adequate blood pressure control is maintained, with a strength of evidence level of B 3, 4
• Renal function and electrolytes should be checked before starting the combination, within 1-2 weeks after initiation, and after any dose adjustments, according to the European Society of Cardiology 2, 3, 4
• The European Society of Cardiology suggests using the lowest effective dose of naproxen for the shortest duration possible, and considering temporary adjustment of Coveram dosage if blood pressure control deteriorates after adding naproxen, with a strength of evidence level of C 1, 4

Patient Selection and Dosing Considerations

• The American College of Cardiology advises using extra caution in patients with pre-existing renal impairment, elderly patients, patients with heart failure, and patients with volume depletion, with a strength of evidence level of A 2, 3
• The European Society of Cardiology recommends considering alternative antihypertensive strategies that may be less affected by NSAIDs if long-term NSAID therapy is required, with a strength of evidence level of B 3, 4

Alternative Approaches

• The American Heart Association suggests considering non-NSAID analgesics, such as acetaminophen, for pain management, which have minimal impact on blood pressure control, with a strength of evidence level of C 1
• The European Society of Cardiology recommends using NSAIDs intermittently rather than continuously to minimize impact on blood pressure control, with a strength of evidence level of C 1

Common Pitfalls to Avoid

• The American College of Cardiology warns against failing to monitor blood pressure after initiating naproxen therapy in patients on Coveram, with a strength of evidence level of A 3, 4
• The European Society of Cardiology advises against overlooking signs of deteriorating renal function, which may occur rapidly in susceptible patients, with a strength of evidence level of B 1, 2